Mark Stenhouse - Net Worth and Insider Trading

Mark Stenhouse Net Worth

The estimated net worth of Mark Stenhouse is at least $4 Million dollars as of 2024-06-08. Mark Stenhouse is the COO of Prometheus Biosciences Inc and owns about 14,000 shares of Prometheus Biosciences Inc (RXDX) stock worth over $3 Million. Mark Stenhouse is also the President, Cologuard of Exact Sciences Corp and owns about 29,926 shares of Exact Sciences Corp (EXAS) stock worth over $1 Million. Details can be seen in Mark Stenhouse's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mark Stenhouse has not made any transactions after 2021-03-16 and currently still holds the listed stock(s).

Transaction Summary of Mark Stenhouse

To

Mark Stenhouse Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mark Stenhouse owns 3 companies in total, including Exact Sciences Corp (EXAS) , Phathom Pharmaceuticals Inc (PHAT) , and Prometheus Biosciences Inc (RXDX) .

Click here to see the complete history of Mark Stenhouse’s form 4 insider trades.

Insider Ownership Summary of Mark Stenhouse

Ticker Comapny Transaction Date Type of Owner
EXAS Exact Sciences Corp 2020-04-03 President & Cologuard
PHAT Phathom Pharmaceuticals Inc 2020-03-17 director
RXDX Prometheus Biosciences Inc 2021-03-16 Chief Operating Officer

Mark Stenhouse Latest Holdings Summary

Mark Stenhouse currently owns a total of 2 stocks. Among these stocks, Mark Stenhouse owns 14,000 shares of Prometheus Biosciences Inc (RXDX) as of March 16, 2021, with a value of $3 Million and a weighting of 68.54%. Mark Stenhouse also owns 29,926 shares of Exact Sciences Corp (EXAS) as of April 3, 2020, with a value of $1 Million and a weighting of 31.46%.

Latest Holdings of Mark Stenhouse

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
RXDX Prometheus Biosciences Inc 2021-03-16 14,000 199.92 2,798,880
EXAS Exact Sciences Corp 2020-04-03 29,926 42.93 1,284,723

Holding Weightings of Mark Stenhouse


Mark Stenhouse Form 4 Trading Tracker

According to the SEC Form 4 filings, Mark Stenhouse has made a total of 1 transactions in Prometheus Biosciences Inc (RXDX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Prometheus Biosciences Inc is the acquisition of 14,000 shares on March 16, 2021, which cost Mark Stenhouse around $266,000.

According to the SEC Form 4 filings, Mark Stenhouse has made a total of 2 transactions in Exact Sciences Corp (EXAS) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Exact Sciences Corp is the sale of 11,948 shares on April 3, 2020, which brought Mark Stenhouse around $677,332.

Insider Trading History of Mark Stenhouse

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mark Stenhouse Trading Performance

GuruFocus tracks the stock performance after each of Mark Stenhouse's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Stenhouse is 28.91%. GuruFocus also compares Mark Stenhouse's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Stenhouse within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mark Stenhouse's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mark Stenhouse

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 13 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 7.38 LIMIT LIMIT LIMIT LIMIT LIMIT

Mark Stenhouse Ownership Network

Ownership Network List of Mark Stenhouse

No Data

Ownership Network Relation of Mark Stenhouse

Insider Network Chart

Mark Stenhouse Owned Company Details

What does Exact Sciences Corp do?

Who are the key executives at Exact Sciences Corp?

Mark Stenhouse is the President & Cologuard of Exact Sciences Corp. Other key executives at Exact Sciences Corp include General Manager & New Ventures Jacob A Orville , SVP & Human Resources Sarah Condella , and Gen. Mgr. & Precision Oncology Brian Baranick .

Exact Sciences Corp (EXAS) Insider Trades Summary

Over the past 18 months, Mark Stenhouse made no insider transaction in Exact Sciences Corp (EXAS). Other recent insider transactions involving Exact Sciences Corp (EXAS) include a net sale of 36,358 shares made by Sarah Condella , a net sale of 7,501 shares made by James Herriott , and a net sale of 81,344 shares made by Kevin T Conroy .

In summary, during the past 3 months, insiders sold 6,762 shares of Exact Sciences Corp (EXAS) in total and bought 0 shares, with a net sale of 6,762 shares. During the past 18 months, 242,269 shares of Exact Sciences Corp (EXAS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 242,269 shares.

Exact Sciences Corp (EXAS)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Exact Sciences Corp Insider Transactions

No Available Data

Mark Stenhouse Mailing Address

Above is the net worth, insider trading, and ownership report for Mark Stenhouse. You might contact Mark Stenhouse via mailing address: 5505 Endeavor Lane, Madison Wi 53719.

Discussions on Mark Stenhouse

No discussions yet.